Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 safety and phase II study in ER-positive breast cancer
ISRCTN80307982Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jul 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fexagratinib in breast cancer (3 arms), sponsored by Imperial College London. Primary endpoints: Dose-limiting toxicities and Change in tumor size at 12 weeks. Started Jul 2012; status: completed.
02
Drugs
fexagratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN80307982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80307982.